US FDA says Pfizer schizophrenia drug ad misleading
WASHINGTON, Aug 13 (Reuters) - A Pfizer Inc. (PFE.N) advertisement for schizophrenia drug Geodon omitted important risk information and contained unsupported claims that it was better than another drug, U.S. regulators said in a letter released on Monday.
The Food and Drug Administration said the ad, which appeared in a medical journal, was misleading. The agency sent a letter to Pfizer that was dated July 16 and posted on the FDA Web site on Monday.
(Reporting by Lisa Richwine)
((Reuters Messaging: lisa.richwine.reuters.com@reuters.net; +1 202 310-5691)) Keywords: PFIZER GEODON/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWBT007393










